Featured Research

from universities, journals, and other organizations

USC Study Shows Raloxifene May Increase Ovarian Cancer Growth Rate

Date:
July 5, 2001
Source:
University Of Southern California
Summary:
The drug raloxifene may increase the growth rate of ovarian cancer and its risk of recurrence, according to researchers from the Keck School of Medicine of the University of Southern California.

LAUSANNE, SWITZERLAND, July 3 –– The drug raloxifene may increase the growth rate of ovarian cancer and its risk of recurrence, according to researchers from the Keck School of Medicine of the University of Southern California.

Related Articles


Speaking at the European Society of Human Reproduction and Embryology’s annual meeting, David Tourgeman, M.D., assistant professor of obstetrics and gynecology at the Keck School, presented data on the effects of raloxifene both alone and in combination with estradiol on ovarian cancer cell lines in the laboratory.

Raloxifene is a selective estrogen receptor modulator (SERM) that has been approved in the United States for use in patients with osteoporosis but has also been looked at as a possible agent for women needing estrogen replacement therapy (ERT). Past research has shown that raloxifene actually has antiestrogenic effects in human breast cancer cells, making it a potentially safe ERT alternative for women who have had breast cancer. In addition, it doesn’t seem to increase the risk of uterine cancer in postmenopausal women.

To date, however, not much work has been done on the drug’s affects on ovarian cancer, despite the fact that ovarian cancer, too, is a hormone-driven disease, noted Tourgeman.

Along with Richard Paulson, M.D., Keck School professor of obstetrics and gynecology, and their USC colleagues, Tourgeman found that both raloxifene and estradiol stimulate cell growth in ovarian adenocarcinoma cells that carried estrogen receptors on their cell surface (ER+ cells)—and that the drugs’ effects occur both when they are given independently and in combination. The cells were exposed to an amount of raloxifene equivalent to that which would be received by the usual 60 mg oral dose of the drug.

"To our knowledge, this is the first time that the effect of raloxifene on ovarian cell lines has been evaluated," said Tourgeman. He notes that there is an ongoing debate as to whether the presence of estrogen receptors on the tumor cells means that estrogen would necessarily cause an ovarian tumor to grow or reappear. Still, he says, "as up to 60 percent of epithelial ovarian cancers and a smaller percentage of anaplastic or recurrent ovarian cancers will be ER+, the most appropriate approach would be one of caution. In contrast to the clinical management of women with a history of breast cancer, raloxifene may not be a good alternative to ERT in women with ER+ ovarian cancer."

Both he and Paulson, however, stressed that this finding does not diminish the recognized benefits of ERT in general for strengthening bone, protecting the cardiovascular system and improving cognition.

That is why, Paulson says, "it would be premature to withhold all forms of ERT from patients with a history of ovarian cancer on the basis of these findings." He and Tourgeman intend to evaluate raloxifene in other cell types to see if it has similar effects. In addition, says Paulson, the hope is that this study will serve as an impetus to other researchers to undertake epidemiologic studies that would evaluate the possible association between raloxifene and ovarian cancer.


Story Source:

The above story is based on materials provided by University Of Southern California. Note: Materials may be edited for content and length.


Cite This Page:

University Of Southern California. "USC Study Shows Raloxifene May Increase Ovarian Cancer Growth Rate." ScienceDaily. ScienceDaily, 5 July 2001. <www.sciencedaily.com/releases/2001/07/010704092406.htm>.
University Of Southern California. (2001, July 5). USC Study Shows Raloxifene May Increase Ovarian Cancer Growth Rate. ScienceDaily. Retrieved October 23, 2014 from www.sciencedaily.com/releases/2001/07/010704092406.htm
University Of Southern California. "USC Study Shows Raloxifene May Increase Ovarian Cancer Growth Rate." ScienceDaily. www.sciencedaily.com/releases/2001/07/010704092406.htm (accessed October 23, 2014).

Share This



More Health & Medicine News

Thursday, October 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
More People Diagnosed With TB In 2013, But There's Good News

More People Diagnosed With TB In 2013, But There's Good News

Newsy (Oct. 22, 2014) The World Health Organizations says TB numbers rose in 2013, but it's partly due to better detection and more survivors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins